Source comparison
CJC-1295 No DAC Mechanism Studies: Comparison of Modified and Unmodified Variants
The table below compares the pharmacological and physiological differences between CJC-1295 with DAC (the albumin-binding variant) and CJC-1295 No DAC (Modified GRF 1-29) based on published mechanism studies. Plasma Half-Life 6–8 days 30–60 minutes DAC modific
This comparison does not assign a generated winner or score.
- The table below compares the pharmacological and physiological differences between CJC-1295 with DAC (the albumin-binding variant) and CJC-1295 No DAC (Modified GRF 1-29) based on published mechanism studies.
- Plasma Half-Life
- 6–8 days
- 30–60 minutes
- DAC modification enables reversible albumin binding, creating slow-release reservoir
- DAC: sustained basal studies; No DAC: pulsatile rhythm studies
- No DAC clears rapidly and preserves natural GH pulse architecture
- GH Release Pattern
- Sustained elevation (flattened curve)
- Pulsatile spikes (90–120 min duration)
- Albumin binding sustains receptor occupation vs rapid clearance
- DAC: chronic elevation protocols; No DAC: circadian rhythm research
- Pulsatile patterns better mimic endogenous secretion
- Dosing Frequency
- 1–2× per week
- 1–3× per day
- Extended half-life reduces dosing frequency
- DAC: convenience in long-term studies; No DAC: flexibility in timing pulses
- No DAC allows researchers to control timing of each GH pulse
- GHRP Synergy
- Minimal (receptor already occupied)
- Maximal (independent pathways converge)
- Continuous receptor activation blunts synergy vs discrete pulses
- No DAC + GHRP stacks produce 3–5× GH vs either alone
- Synergy requires pulsatile dosing. DAC eliminates this advantage
- Clearance Route
- Slow albumin dissociation + renal filtration
- Rapid renal filtration + enzymatic degradation
- DAC delays clearance by binding plasma proteins
- DAC: fewer injections; No DAC: faster washout between doses
- No DAC clears completely within 4 hours, DAC persists for days